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depression (3.5%) was mostly unchanged (Baseline-Wk8; P =
0.059). Clinical depression (patient-reported) was associated
with increased bothersomeness of other symptoms (fatigue, loss
of appetite, nervousness) at Baseline & Wk8 (P < 0.05). CON-
CLUSIONS: Patient-reported depression outcomes should be
valued during HIV treatment, as more patients who were viro-
logically controlled but experiencing Grade 2 PI/NNRTI-
associated side effects self-reported signs of clinical depression
than were diagnosed by physicians. Prevalence of clinical depres-
sion was reduced following substitution to LPV/r.
PIN25
ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE
MEASURES IN HIV AND AIDS
Clayson DJ1,Wild DJ1, Quarterman P1, Coons SJ2, Duprat-Lomon I3,
Kubin M4
1Oxford Outcomes Ltd, Oxford, Oxon, UK; 2The University of
Arizona College of Pharmacy,Tucson, AZ, USA; 3Bayer Pharma,
Puteaux Cedex, Paris, France; 4Bayer HealthCare, Wuppertal,
Elberfeld, Germany
OBJECTIVES: The widespread use of highly active antiretrovi-
ral therapy (HAART) has greatly prolonged life expectancy in
patients with HIV. Therefore, health-related quality of life
(HRQoL) has become an increasingly important endpoint in
clinical trials to assess interventions for people with HIV. We
reviewed the HRQoL measures that have been used in HIV/AIDS
since 1990 to establish the most appropriate measures to use in
future research and clinical trials. METHODS: A comprehen-
sive, unbiased review of generic and HIV-speciﬁc HRQoL mea-
sures was conducted using predeﬁned selection criteria. Generic
and HIV-speciﬁc measures were assessed for practicality (length,
administration time and mode). Generic measures were also
assessed for their ability to elicit utility data and provide nor-
mative values. Measures of HRQoL that were considered prac-
tical and were capable of producing utility data and normative
values (generic measures) were assessed in detail in terms of their
psychometric properties, patient derived content (HIV-speciﬁc
measures), and use in clinical trials. RESULTS: Two generic mea-
sures (EuroQol ﬁve Dimension [EQ-5D] and Medical Outcomes
Study [MOS] Short Form 36 [SF-36]) and six HIV-speciﬁc mea-
sures met the initial selection criteria and were reviewed in full.
EQ-5D and SF-36 were very similar in terms of the selection cri-
teria and two HIV-speciﬁc measures (Functional Assessment of
HIV Infection [FAHI] and MOS-HIV) were selected on the basis
of their superior psychometric properties. CONCLUSIONS: We
recommend using either the EQ-5D with the MOS-HIV, or the
SF-36 with the FAHI to assess HRQoL in HIV/AIDS patients
when planning future research. Administration of these measures
in combination would enable utility scores to be calculated,
patient scores to be compared with normative data, and disease-
speciﬁc HRQoL to be assessed. Future research should concen-
trate on the sensitivity of the different measures at each stage of
infection in patients on HAART.
PIN26
VALIDATION OF 5-ITEM INSTRUMENT FOR ASSESSING
SYMPTOM SEVERITY IN PATIENTS WITH ACUTE BACTERIAL
SINUSITIS
Taylor DC1, Norman GR2,Torrance G3,Thompson D1,Amorosi SL1,
Asche CV4, Patel M4, Lavin B4, Ferguson B5
1Innovus Research, Inc, Medford, MA, USA; 2McMaster University,
Hamilton, ON, Canada; 3Innovus Research, Inc, Burlington, ON,
Canada; 4Aventis Pharmaceuticals, Bridgewater, NJ, USA; 5University
ENT Specialists, Inc, Pittsburgh, PA, USA
OBJECTIVES: To validate a symptom assessment instrument for
patients with acute bacterial sinusitis (ABS). METHODS: Data
were obtained from a randomized, double-blind, equivalency
study of adults with radiographic evidence of ABS treated with
telithromycin 800mgod for 5 days (n = 159) or moxiﬂoxacin
400mgod for 10 days (n = 163). A 5-item Acute Sinusitis Daily
Symptom Survey (ASDSS) was developed for use in the trial. The
ﬁve items of the ADSS (nasal congestion, runny nose, postnasal
discharge, thick nasal discharge, and facial pain/pressure) used a
six-point adjectival scale ranging from zero (“no problem”) to
ﬁve (“problem as bad as it can be”). Overall ASDSS score was
the sum of item responses. Subjects completed the ASDSS daily
for the ﬁrst 17 days of the study. At Visits 1 (Day 1) 2 (Day 3–5),
and 4 (Day 17–24), subjects were assessed for quality of life (SF-
36, acute form), treatment outcomes (success/failure), and infec-
tion-related signs/symptoms. Data were pooled across treatment
groups. RESULTS: Survey completion rates ranged from 100%
(Day 3) to 79.8% (Day 17). Pearson correlations between the
ASDSS items ranged from 0.258 to 0.639. Test-retest intraclass
correlation coefﬁcients (ICC) measured over a 5 day interval
(Day 1–5) were: nasal congestion (0.681), runny nose (0.612),
postnasal discharge (0.689), thick nasal discharge (0.669), and
facial pain/pressure (0.679). Cronbach’s alpha was 0.788 and
test-retest reliability (ICC) of the total score was 0.694. Pearson
correlations between ASDSS and the SF-36 scales at Visit 4
ranged from -0.293 (mental health) to -0.496 (vitality). Pearson
correlations with the ASDSS at Visit four were 0.599 for major
and 0.634 for minor symptoms of infection. Mean ASDSS scores
at Visit four were 3.34 for subjects deemed treatment successes
and 10.35 for treatment failures (F = 2.60, p < 0.0001). CON-
CLUSIONS: The ASDSS appears to be a valid symptom assess-
ment instrument for patients with ABS.
PIN27
WILLINGNESS TO PAY FOR PREVENTION AND TREATMENT
OF TUBERCULOSIS (TB) IN RURAL NEPAL: A CONTINGENT
VALUATION STUDY
Paudel L1,Adhikari M1, Devkota N2
1The University of Georgia, Athens, GA, USA; 2Lousiana State
University, Baton Rouge, LA, USA
OBJECTIVES: In the mountain kingdom of Nepal, nearly
44,000 new cases of the tuberculosis (TB) appear every year. This
study explores community valuation of TB prevention by esti-
mating household and community willingness to pay (WTP) for
the prevention of transmission and treatment of TB in the rural
areas of mid-Nepal. METHODS: A contingent valuation survey
was used to assess individual WTP for speciﬁc prevention and
treatment interventions for TB. In order to estimate conﬁdence
limits in mean WTP and to generate a distribution of WTP for
the community, accounting for uncertainty in regression coefﬁ-
cients and variability within the population, a two-dimensional
Monte Carlo simulation was also developed. RESULTS: The
study results show a mean WTP of $0.81 per month per house-
hold (90% CL: $0.43, $1.61) to prevent transmission of TB.
However, the mean WTP for TB treatment was estimated to be
$2.31 per month (90% CL: $1.32, $3.47) per household. Nearly
22% and 47% of household were not willing to pay for pre-
vention and treatment of TB, respectively. As expected, income
positively affected estimates of mean WTP for both TB treatment
and prevention. An individual’s familiarity with TB and super-
stitions signiﬁcantly negatively inﬂuenced WTP for treatment
and prevention. Contrary to expectation, WTP for TB treatment
and prevention was not inﬂuenced by religion and ethnicity in
the rural villages of Nepal. In our study, sex and health educa-
tion do not show any signiﬁcant affects on WTP for transmission
prevention and treatment interventions of TB. CONCLUSIONS:
These results show that the majority of the community places a
positive value on both prevention and treatment of TB. Mean
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WTP provides monetary estimate of over all beneﬁt of TB 
prevention and treatment program. The study results suggest
socio-economic factors and knowledge about TB as major deter-
minants of WTP.
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OBJECTIVES: Lipodystrophy may have a great impact on
quality of life (QoL). Current HIV speciﬁc instruments do not
measure this impact. We performed a cultural adaptation and
psychometric validation in French of a new lipodystrophy spe-
ciﬁc instrument Assessment of Body Change and Distress
(ABCD). METHODS: ABCD consists of three parts: signs of
lipodystrophy (6 items), global satisfaction (1 item) and 20 QoL
items. Items were generated in US. Our study consisted of two
parts: 1) Cultural adaptation; 2) Psychometric validation in a
survey in comparison with speciﬁc (MOS-HIV) and generic (SF-
12) QoL questionnaires. RESULTS: The approach of French
patients was to some extent different from US patients, and
needed cultural adaptation of several concepts. A total of 155
HIV French outpatients (143 with lipodystrophy) from 2
Parisian hospitals and one general practice were included. Mean
age was 43 ± 10yrs. Mean duration of HAART was 4.5 ± 1.7
yrs. Discriminant validity: QoL scores decreased according to the
number of sites with lipodystrophy, ranging from 85 ± 16 (none)
to 42 ± 10 (6 sites), p < 0.001, and according to whether patients
were thinking about plastic surgery or not, from 68 ± 20 (never)
to 33 ± 13 (always), p < 0.001. Internal consistency was high
(Cronbach alpha = 0.94). Factorial analysis yielded a 4-factor
structure. Convergent validity: the highest correlations were
between ABCD QoL and health distress and social dimensions
of the MOS-HIV (r > 0.6) and with the mental component of
the SF-12 (r = 0.65). CONCLUSIONS: The psychological and
social distress related to the body changes must be measured in
clinical trials, to make sure that life is not lengthened at the
expense of its quality. ABCD questionnaire is a validated ques-
tionnaire which can now be used in French.
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OBJECTIVES: Investigate the role economic evaluations played
in supporting decision making for meningococcal C conjugate
(MCC) vaccination. METHODS: We performed an extensive lit-
erature review (Pubmed, Embase, HEED, NEED) and contacted
experts to identify a) the incidence of meningococcal C disease,
and b) economic evaluations for MCC immunisation pro-
grammes and their inﬂuence on decision making. RESULTS:
Data were obtained for Australia, Canada, Israel, the US and 17
European countries. The yearly meningococcal C incidence per
100,000 persons varied between 0.04 (Italy) and 4.91 (Iceland)
in 2001. Ten countries have implemented MCC vaccination pro-
grammes. In all of them except Greece high meningococcal C
incidence was reported between 1999 and 2001 (one year ≥0.8
per 100,000) but economic evaluations were performed in only
four. While economic evaluation inﬂuenced decision making
strongly in Australia, Canada (Quebec) and The Netherlands, its
impact was limited in the UK. Of the 11 countries without MCC
vaccination programmes, only Portugal and Switzerland con-
ducted economic evaluations. These were performed after the
initial decision to not implement MCC vaccination was made,
but nonetheless (may) inform subsequent decision making in
both countries. All reviewed economic evaluations were model-
ling studies, each showing that routine childhood MCC vacci-
nation is slightly less effective but much more cost-effective early
in the second year of life (about 2500€ to 19,000€ per life-year
or QALY gained) than during the ﬁrst year of life (about 42,400€
to 2.4m€ per additionally gained life-year or QALY compared
to immunisation in the second year). The reported results were
most sensitive to meningococcal C incidence, vaccine price and
speciﬁc methodological characteristics. CONCLUSIONS: Only
in a minority of investigated countries economic evaluation of
MCC vaccination inﬂuenced decision making. The divergence
and importance of methodological characteristics in the analysed
studies demonstrates the need of ﬁrmer international guidelines
and better adherence to these guidelines.
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Some of the expected adverse drug reactions of the systemic tri-
azole antifungals (ﬂuconazole and itraconazole) can be attrib-
uted to drug-drug interactions. OBJECTIVES: To quantify the
frequency of concurrent drug use that may cause drug-drug inter-
actions (DDI) with triazole antifungals. METHODS: A retro-
spective observational study was conducted of adult patients
who received systemic triazole treatment in 6 hospitals compris-
ing the PHARMO Inpatient database during 1994–2002. The
list of triazole interacting drugs, the severity and effect of inter-
action was obtained from the Drug-Reax® system and the Drug
Interaction Facts. Concomitant use of triazole interacting drugs
was identiﬁed for each day of systemic triazole treatment.
RESULTS: The study cohort comprised 1374 patients with a
total of 1522 hospitalizations during which ﬂuconazole (n =
1329) or itraconazole (n = 193) were prescribed. The majority
of hospitalizations were for neoplasms (21.6%), respiratory
(15.2%) and digestive disease (14.3%). The median duration of
triazole treatment was eight days. Among patients receiving ﬂu-
conazole, 55.3% were prescribed at least one interacting drug
(>95% with potential for moderate or severe consequences) with
32.5% of patients receiving more than one interacting drug. The
most frequently co-prescribed interacting drugs with ﬂuconazole
were haloperidol, digoxin, prednisolone, acencoumarol and
theophylline. Among patients on itraconazole, 65.3% received
at least 1 interacting co-prescription (74% moderate or severe),
41% received more than one interacting drug. The most fre-
quently co-prescribed interacting drugs with itraconazole were
ranitidine, acenocoumarol, prednisolone, pantoprazole and
theophylline. The most frequent occurring effect of the DDI
